2) Farber EM, Nail ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974 ; 148 : 1-18.
3) 小澤明. 乾癬. 疫学・統計. 山村雄一ほか (編). 現代皮膚科学大系 第4巻B 角化異常性疾患 II. 中山書店 ; 1981. pp.3-11.
5) Henseler T, Christophers E. Psoriasis of early and late onset : Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985 ; 13 : 450-6.
6) Lew W, Lee E, Krueger JG. Psoriasis genomics : Analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. Br J Dermatol 2004 ; 150 : 668-76.
7) Kim J, Oh CH, Jeon J, et al. Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL?17 Pathway Genes but Different Regulatory Gene Sets. J Invest Dermatol 2016 ; 136 : 161-72.
8) Ozawa A, Ohkido M, Tsuji K. Some recent advances in HLA and skin diseases. J Am Acad Dermatol 1981 ; 4 : 205-30.
9) Mabuchi T, Ota T, Manabe Y, et al. HLA-C*12 : 02 is a susceptibility factor in late-onset type of psoriasis in Japanese. J Dermatol 2014 ; 41 : 697-704.
10) 小澤明. 尋常性乾癬における主要組織適合抗原-II. DR (Drelated) 抗原の解析. 日皮会誌 1978 ; 88 : 981-92.
11) Mabuchi T, Oka A, Iizuka M, et al. Fine mapping of a psoriasis?susceptibility locus within the HLA class II region by using microsatellite markers in an association study of Japanese cases and controls. Tokai J Exp Clin Med 2007 ; 32 : 6-13.
12) Mabuchi T, Hirayama N. Binding Affinity and Interaction of LL-37 with HLA-C*06 : 02 in Psoriasis. J Invest Dermatol 2016 ; 136 : 1901-3.
13) Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T?cell autoantigen in psoriasis. Nat Commun 2014 ; 5 : 5621.
14) Yunusbaeva M, Valiev R, Bilalov F, et al. Psoriasis patients demonstrate HLA-Cw*06 : 02 allele dosage-dependent T cell proliferation when treated with hair follicle?derived keratin 17 protein. Sci Rep 2018 ; 8 : 6098.
15) Arakawa A, Siewert K, Stohr J, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 2015 ; 212 : 2203-12.
17) 馬渕智生, 小澤明. 乾癬の疾患遺伝子. 古江増隆, 大槻マミ太郎 (編). 皮膚科臨床アセット 10 ここまでわかった乾癬の病態と治療. 中山書店 ; 2012. pp.6-10.
18) Tomfohrde J, Silverman A, Barnes R, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994 ; 264 : 1141-5.
19) Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 2012 ; 90 : 784-95.
20) Riveira-Munoz E, He SM, Escaramis G, et al. Meta-Analysis Confirms the LCE3C_LCE3B Deletion as a Risk Factor for Psoriasis in Several Ethnic Groups and Finds Interaction with HLA-Cw6. J Invest Dermatol 2011 ; 131 : 1105-9.
21) Li K, Huang CC, Randazzo B, et al. HLA-C*06 : 02 Allele and Response to IL-12/23 Inhibition : Results from the Ustekinumab Phase 3 Psoriasis Program. J Invest Dermatol 2016 ; 136 : 2364-71.
22) Costanzo A, Bianchi L, Flori ML, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis : SUPREME study. Br J Dermatol 2018 ; 179 : 1072-80.
23) Eder L, Chandran V, Gladman DD. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis? Curr Opin Rheumatol 2015 ; 27 : 91-8.
24) FitzGerald O, Haroon M, Giles JT, et al. Concepts of pathogenesis in psoriatic arthritis : Genotype determines clinical phenotype. Arthritis Res Ther 2015 ; 17 : 115.